Patheon Inc. Expands Manufacturing Facility in Ferentino, Italy

    
    Expansion Increases Capacity for Pharmaceutical Development Services and
    Commercial Manufacturing

    Source: Patheon Inc.
    Website: www.patheon.com
    

RESEARCH TRIANGLE PARK, NC, Sept. 24 /CNW/ - Patheon Inc. (TSX: PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, announced today it has opened a new Pharmaceutical Development Services (PDS) manufacturing site for investigational medical products within its existing manufacturing facility in Ferentino, Italy .

Patheon Inc. CEO Wes Wheeler stated, "Our new PDS facility will be of strategic importance in order to feed the pipeline of Patheon's two commercial sites located in Italy , offering clients a one stop shop, from early development all the way through to commercial manufacturing."

The new facility will be dedicated to the manufacture of sterile products including aseptically filled, terminally sterilized liquids and lyophilization. It also includes development and quality control laboratories. Three lyophilization units will be available: two dedicated to development activities for non-human use and one dedicated to the manufacture of clinical trial materials.

The area, which has been designed to accommodate future expansion, is set up specifically for the scale-up of products for clinical use following the completion of development activities on site and will be a key support mechanism for the manufacture of biopharmaceutical products.

Special capabilities will include the manufacture of highly potent drugs, poorly soluble, oxygen and light sensitive compounds, and highly hygroscopic lyo products. The space is also equipped with a dedicated water and HVAC system.

The expansion will double PDS manufacturing capabilities for clinical batches, and analytical laboratory capabilities have been doubled to support the subsequent increased volume of projects. The new area will be completed for use in November 2009 and will employ an additional 10 process specialists and development scientists.

ABOUT PATHEON INC.

Patheon Inc. (TSX: PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 300 pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through the commercial manufacturing of a wide array of dosage forms including parenteral, solid, semi-solid and liquids. Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical supplies, scale-up and commercialization. Patheon's ability to integrate development and manufacturing services ensures that our customers' projects are delivered on time and meet the high standards of quality that Patheon is known for.

Patheon's integrated development and manufacturing network of 11 facilities and 8 development centers, across North America and Europe , strives to ensure that customer products can be launched timely and confidently anywhere in the world.

Caution Concerning Forward-Looking StatementsThis news release may contain forward-looking statements which reflect management's expectations regarding the Company's future growth of operations, performance (both operational and financial) and business prospects and opportunities. These statements are made in the context of the risks and uncertainties that are outlined in the Company's public documents, which can be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.

%SEDAR: 00001700E

For further information: Mr. Wes Wheeler, President and Chief Executive Officer, Tel: [phone], Email: [email protected]; Mr. Eric Evans, Chief Financial Officer, Tel: [phone], Email: [email protected]; Ms. Wendy Wilson, Investor Relations, Tel: [phone], Email: [email protected]